Navigation Links
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
Date:9/28/2008

LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ --

- Results Presented at World Stroke Congress in Vienna

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The trial showed that microplasmin was generally well tolerated and also provided some interesting preliminary efficacy data. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at a Late-Breaking Clinical Trial session at the World Stroke Congress.

The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety and preliminary efficacy of the intravenous administration of microplasmin in 40 patients, 4 to 12 hours after onset of acute ischemic stroke. The trial investigated three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) compared to placebo. Clinical outcomes were assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments were performed.

The study found that microplasmin was generally well tolerated with no evidence of increased bleeding risk; there were no systemic bleeding events reported and there was no evidence of increased rate of bleeding in general, in those patients that had been treated with microplasmin compared to those treated with placebo.

In addition, the study provided some interesting preliminary efficacy results. Approximately 25% of patients treated with microplasmin had reperfusion (restoration of blood flow) within eight hours of being treated, this compares with 10% of placebo-treated patients. Moreover, of the patients who had more severe vascular blockages, 33% of patients treated with microplasmin achieved reperfusion compared with 14% of placebo-treated patients. Due to the small number of patients in this study, neither of these end points were statistically significant. However, the study also showed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

Professor Vincent Thijs, Lead Principal Investigator of the trial, commenting on the results said, "I am delighted that we were able to present these interesting results at the World Stroke Congress. The results show that microplasmin is safe and generally well tolerated with no evidence of increased bleeding risk. Moreover, the results also support previous preclinical studies that have shown that microplasmin is able to lyse clots and may also have certain vascular protective properties."

Dr. Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have been able to successfully conclude this study of microplasmin in patients with stroke. The results that have been reported show that the product is well tolerated and could potentially be of benefit in this indication of high medical need. However, as we have stated previously, our current view is that it only makes sense for ThromboGenics to move forward with the development of microplasmin for vascular indications in cooperation with a partner, given the costs and risks involved. We believe that by focusing on the development of microplasmin for eye disease, where we have already generated encouraging clinical data, and carefully utilizing our resources on the other opportunities in our pipeline, we will continue to generate a high return for ThromboGenics' shareholders."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact:

ThromboGenics

Patrik De Haes, CEO Tel : +32-16-75-13-10

patrik.dehaes@thrombogenics.com

Desire Collen, Chairman Tel : +32-16-75-13-10

desire.collen@thrombogenics.com

Citigate Dewe Rogerson

Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71

amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 ... and instruments commonly used in laboratories. These may range ... scale condensers. Laboratory glassware is made from borosilicate glass ... shock. Laboratory plasticware, on the other hand, started gaining ... that it was easier to replace glass with plastic ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology:
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... As ... a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself ... dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center ... Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop event ... The workshops cover a broad range of topics, including coaching skills, the scientific ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
Breaking Medicine News(10 mins):